BGI Genomics(SZ:300676) Sou Hu Cai Jing·2025-08-27 09:45Core Viewpoint - BGI Genomics reported a significant decline in both revenue and profit for the first half of 2025, indicating ongoing financial challenges for the company [1][3]. Financial Performance - For the first half of 2025, BGI Genomics' operating revenue was 1.631 billion yuan, a year-on-year decrease of 12.82% [1]. - The net profit attributable to shareholders was 5.7782 million yuan, down 68.25% year-on-year [1]. - The non-recurring net profit attributable to shareholders was -30.4881 million yuan, a drastic decline of 2610.77% year-on-year [1]. - Basic earnings per share were 0.01 yuan [1]. - The gross margin for the first half of 2025 was 44.65%, a decrease of 2.59 percentage points compared to the previous year [1]. - The net profit margin was 0.25%, down 0.82 percentage points year-on-year [1]. Expense Management - Total operating expenses for the first half of 2025 were 642 million yuan, a reduction of 149 million yuan compared to the previous year [1]. - The expense ratio was 39.37%, down 2.93 percentage points year-on-year [1]. - Sales expenses decreased by 15.51%, management expenses fell by 15.94%, R&D expenses were down by 9.05%, and financial expenses decreased by 140.00% [1]. Company Overview - BGI Genomics, established on July 9, 2010, is located in Shenzhen, Guangdong Province, and was listed on July 14, 2017 [2]. - The company specializes in providing research services and comprehensive solutions for precision medicine testing through various genomic and analytical technologies [2].